0000899243-19-029433.txt : 20191217 0000899243-19-029433.hdr.sgml : 20191217 20191217164223 ACCESSION NUMBER: 0000899243-19-029433 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191217 FILED AS OF DATE: 20191217 DATE AS OF CHANGE: 20191217 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Faga Daniel CENTRAL INDEX KEY: 0001673528 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36819 FILM NUMBER: 191290250 MAIL ADDRESS: STREET 1: 3737 MARKET STREET STREET 2: SUITE 1300 CITY: PHILADELPHIA STATE: PA ZIP: 19104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Spark Therapeutics, Inc. CENTRAL INDEX KEY: 0001609351 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 462654405 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3737 MARKET STREET STREET 2: SUITE 1300 CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: 888-772-7560 MAIL ADDRESS: STREET 1: 3737 MARKET STREET STREET 2: SUITE 1300 CITY: PHILADELPHIA STATE: PA ZIP: 19104 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-12-17 1 0001609351 Spark Therapeutics, Inc. ONCE 0001673528 Faga Daniel 3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104 0 1 0 0 Chief Business Officer Common Stock 2019-12-17 4 U 0 38828 114.50 D 0 D Stock Option (Right to Buy) 42.73 2019-12-17 4 D 0 35000 0.00 D 2029-01-15 Common Stock 35000 0 D Stock Option (Right to Buy) 50.55 2019-12-17 4 D 0 26250 0.00 D 2028-01-17 Common Stock 26250 0 D Stock Option (Right to Buy) 56.17 2019-12-17 4 D 0 14000 0.00 D 2027-01-17 Common Stock 14000 0 D Stock Option (Right to Buy) 37.62 2019-12-17 4 D 0 50000 0.00 D 2026-05-01 Common Stock 50000 0 D Restricted Stock Units 0.00 2019-12-17 4 D 0 21500 0.00 D Common Stock 21500 0 D Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings). /s/ Joseph W. La Barge, Attorney-in-Fact 2019-12-17